Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $38.24, but opened at $37.05. Ascentage Pharma Group International shares last traded at $36.31, with a volume of 8,478 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, JPMorgan Chase & Co. began coverage on Ascentage Pharma Group International in a research note on Thursday, March 27th. They set an "overweight" rating on the stock.
Read Our Latest Report on AAPG
Ascentage Pharma Group International Trading Up 2.6%
The company has a debt-to-equity ratio of 3.24, a current ratio of 1.26 and a quick ratio of 1.26. The company has a 50-day moving average of $31.95.
Institutional Trading of Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new position in shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned 0.18% of Ascentage Pharma Group International at the end of the most recent quarter.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Further Reading
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access